Anti-acetylcholinesterase-a review Haruo Hanyu 1 1Department of Geriatric Medicine, Tokyo Medical University Keyword: アルツハイマー病 , アセチルコリン , donepezil , galantamine , rivastigmine pp.461-470
Published Date 2005/6/10
DOI https://doi.org/10.11477/mf.1431100063
  • Abstract
  • Look Inside

This article reviews evidence indicating that acetylcholinesterase inhibitors have psychotropic properties. Cholinesterase inhibitors, including donepezil, galantamine, and rivastigmine, are currently approved for the treatment of Alzheimer's disease. The clinical effects include an improvement and stabilization of cognitive function, positive effect on emotional/behavioral symptoms, maintenance or slowed decline of functional abilities, less caregiving time and lower levels of caregiver stress, fewer delays in nursing home placement, and greater cost-effectiveness with good tolerability. In addition to mild to moderate stages of Alzheimer's disease, benefits extend into very early Alzheimer's disease or mild cognitive impairment, and even more advanced stages of the disease. Clinical trials of cholinesterase inhibitors are encouraged to establish their precise role in vascular dementia, dementia with Lewy bodies, and Parkinson's disease with dementia. Recent studies suggest that cholinesterase inhibitors may have a potentially protective effect in Alzheimer's disease by preventing apoptotic cell death or activating nerve growth factor.

Copyright © 2005, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1882-1243 印刷版ISSN 0001-8724 医学書院